These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8700537)

  • 1. An abundance of p53 null mutations in ovarian carcinoma.
    Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
    Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distant metastases in ovarian cancer: association with p53 mutations.
    Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
    Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer genomic instability correlates with p53 frameshift mutations.
    Sood AK; Skilling JS; Buller RE
    Cancer Res; 1997 Mar; 57(6):1047-9. PubMed ID: 9067268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of p53 gene in gastric carcinoma in Taiwan.
    Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
    Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
    Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
    Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism.
    Oyasu R; Nan L; Szumel RC; Kawamata H; Hirohashi S
    Mod Pathol; 1995 Feb; 8(2):170-6. PubMed ID: 7777479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of p53 gene in primary gastric cancer tissues.
    Hong SI; Hong WS; Jang JJ; Lee DS; Cho NS; Jung ME; Kim HB; Ha GW; Park IC; Cho DS
    Anticancer Res; 1994; 14(3B):1251-5. PubMed ID: 8067692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
    Saitoh S; Cunningham J; De Vries EM; McGovern RM; Schroeder JJ; Hartmann A; Blaszyk H; Wold LE; Schaid D; Sommer SS
    Oncogene; 1994 Oct; 9(10):2869-75. PubMed ID: 8084591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutation is a common genetic event in ovarian carcinoma.
    Milner BJ; Allan LA; Eccles DM; Kitchener HC; Leonard RC; Kelly KF; Parkin DE; Haites NE
    Cancer Res; 1993 May; 53(9):2128-32. PubMed ID: 8481915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.
    Buller RE; Shahin MS; Holmes RW; Hatterman M; Kirby PA; Sood AK
    Am J Obstet Gynecol; 2001 Apr; 184(5):891-902; discussion 902-3. PubMed ID: 11303196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
    Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
    Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infrequent p53 gene mutations and lack of p53 protein expression in clear cell sarcoma of the kidney: immunohistochemical study and mutation analysis of p53 in renal tumors of unfavorable prognosis.
    Hsueh C; Wang H; Gonzalez-Crussi F; Lin JN; Hung IJ; Yang CP; Jiang TH
    Mod Pathol; 2002 Jun; 15(6):606-10. PubMed ID: 12065773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
    Geisler JP; Hatterman-Zogg MA; Rathe JA; Lallas TA; Kirby P; Buller RE
    Hum Mutat; 2001 Oct; 18(4):337-44. PubMed ID: 11668617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
    Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
    Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.